Markus Raderer Selected Research

Marginal Zone B-Cell Lymphoma (MALT Lymphoma)

1/2022	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication.
1/2021	How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies.
1/2021	Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma.
11/2020	First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna.
10/2020	Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
8/2020	Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna.
2/2020	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
1/2020	How I treat MALT lymphoma: 'a subjective interpretation of the gospel according to Isaacson….'
12/2019	Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy.
10/2019	Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Raderer Research Topics

Disease

61	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2022 - 09/2002
43	Neoplasms (Cancer) 09/2022 - 03/2002
38	Lymphoma (Lymphomas) 01/2022 - 09/2002
9	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2021 - 01/2009
7	Diarrhea 10/2021 - 01/2002
7	Disease Progression 10/2021 - 01/2009
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 10/2004
6	Infections 01/2022 - 03/2002
6	B-Cell Lymphoma (Lymphoma, B Cell) 06/2021 - 03/2013
5	Multiple Myeloma 02/2018 - 01/2004
4	Fatigue 10/2021 - 04/2003
4	Nausea 01/2021 - 01/2002
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 08/2003
4	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 01/2011
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2010 - 01/2005
3	COVID-19 01/2022 - 10/2020
3	Inflammation (Inflammations) 11/2019 - 03/2002
3	Breast Neoplasms (Breast Cancer) 11/2019 - 05/2002
3	Adenocarcinoma 01/2018 - 06/2008
3	Stomatitis 03/2016 - 05/2002
3	Autoimmune Diseases (Autoimmune Disease) 03/2016 - 08/2014
3	Esophageal Neoplasms (Esophageal Cancer) 12/2011 - 07/2007
3	Neutropenia 10/2004 - 01/2002
3	Vomiting 04/2003 - 01/2002
3	Colorectal Neoplasms (Colorectal Cancer) 04/2003 - 01/2002
2	Neuroendocrine Carcinoma 01/2021 - 01/2009
2	Head and Neck Neoplasms (Head and Neck Cancer) 10/2020 - 01/2017
2	Carcinoid Tumor (Carcinoid) 01/2019 - 08/2016
2	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 08/2003
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 01/2017
2	Neoplasm Metastasis (Metastasis) 10/2017 - 08/2002
2	Anaplastic Thyroid Carcinoma 10/2016 - 09/2010
2	Heart Diseases (Heart Disease) 12/2015 - 02/2010
2	Familial primary gastric lymphoma 06/2015 - 10/2005
2	Pathologic Complete Response 01/2015 - 02/2012
2	Paraproteinemias (Monoclonal Gammopathy) 08/2014 - 11/2004

Drug/Important Bio-Agent (IBA)

23	Rituximab (Mabthera)FDA Link 06/2021 - 01/2003
9	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 03/2006
8	Clarithromycin (Biaxin)FDA LinkGeneric 01/2021 - 12/2011
8	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2015
7	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2013 - 01/2002
6	Pharmaceutical PreparationsIBA 01/2022 - 05/2003
6	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020 - 08/2003
6	Lenalidomide (CC 5013)FDA Link 10/2019 - 03/2013
6	Cladribine FDA LinkGeneric 06/2017 - 09/2002
5	Biological ProductsIBA 01/2022 - 08/2015
5	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2021 - 07/2014
5	Antineoplastic Agents (Antineoplastics)IBA 08/2021 - 12/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 06/2019 - 01/2004
5	Everolimus FDA Link 01/2018 - 07/2014
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2016
4	68Ga-pentixaforIBA 01/2022 - 01/2018
4	AntigensIBA 01/2020 - 09/2012
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2018 - 01/2006
4	Thalidomide (Thalomid)FDA Link 01/2016 - 01/2004
4	Mitoxantrone (Novantrone)FDA LinkGeneric 09/2012 - 02/2005
4	Docetaxel (Taxotere)FDA Link 09/2010 - 05/2002
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2008 - 05/2002
3	AntibodiesIBA 01/2022 - 11/2016
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2018
3	Chemokine ReceptorsIBA 01/2019 - 11/2016
3	Bortezomib (Velcade)FDA Link 11/2018 - 05/2009
3	Vincristine (Oncovin)FDA LinkGeneric 11/2018 - 01/2006
3	Prednisone (Sone)FDA LinkGeneric 11/2018 - 02/2005
3	Cisplatin (Platino)FDA LinkGeneric 11/2008 - 01/2003
3	Irinotecan (Camptosar)FDA LinkGeneric 07/2007 - 01/2002
2	Monoclonal AntibodiesIBA 06/2021 - 01/2021
2	Azithromycin (Zithromax)FDA LinkGeneric 01/2021 - 02/2019
2	MacrolidesIBA 01/2021 - 02/2019
2	Immunomodulating AgentsIBA 11/2020 - 01/2016
2	Cytostatic AgentsIBA 11/2020 - 02/2010
2	Bendamustine Hydrochloride FDA Link 06/2019 - 02/2014
2	Ondansetron (Zofran)FDA LinkGeneric 01/2019 - 05/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2018 - 01/2006
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2018 - 09/2012
2	purineIBA 06/2017 - 08/2015
2	Bevacizumab (Avastin)FDA Link 01/2017 - 08/2005
2	NivolumabIBA 01/2017 - 01/2016
2	Chlorambucil (Leukeran)FDA Link 01/2017 - 02/2005
2	ParaproteinsIBA 01/2017 - 11/2004
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2016 - 11/2005
2	somatostatin receptor 2IBA 11/2016 - 10/2016
2	Octreotide (Sandostatin)FDA LinkGeneric 08/2016 - 12/2005
2	Tumor Biomarkers (Tumor Markers)IBA 08/2016 - 08/2013
2	Hormones (Hormone)IBA 12/2015 - 07/2014
2	Peptides (Polypeptides)IBA 12/2015 - 05/2003
2	AnthracyclinesIBA 08/2015 - 02/2010
2	Deoxyglucose (2 Deoxy D glucose)IBA 06/2015 - 01/2004

Therapy/Procedure

56	Therapeutics 01/2022 - 01/2002
23	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
5	Precision Medicine 01/2022 - 01/2018
5	Immunotherapy 11/2020 - 08/2002
5	Radiotherapy 01/2019 - 02/2010
4	Aftercare (After-Treatment) 10/2021 - 09/2005
4	Stem Cell Transplantation 01/2017 - 01/2005
2	Drug Tapering 10/2021 - 05/2009
2	Transplantation 11/2018 - 01/2015
2	Salvage Therapy 01/2017 - 01/2016
2	Hematopoietic Stem Cell Mobilization 01/2017 - 02/2006
2	Hematopoietic Stem Cell Transplantation 01/2015 - 09/2007